A U.S. Patent for “Modulation of Charge Variants in a Monoclonal Antibody” was awarded to Outlook Therapeutics on June 30th, 2020. The present invention is a process for removing acid charge variants from a monoclonal antibody, comprising (a) loading a mammalian cell-expressed monoclonal antibody preparation onto a Protein A support, and eluting the monoclonal antibody from the Protein A support, thereby producing a first eluate comprising the monoclonal antibody; (b) loading the first eluate from step (a) onto an anion exchange and hydrophobic interaction (AEX/HIC) chromatography support, and allowing the first eluate to flow. Learn More